<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134489">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01906879</url>
  </required_header>
  <id_info>
    <org_study_id>201304017MINB</org_study_id>
    <nct_id>NCT01906879</nct_id>
  </id_info>
  <brief_title>Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection</brief_title>
  <official_title>Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <authority>Department of Health: Taiwan</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Whether non-bismuth quadruple therapy (concomitant therapy) is more effective than bismuth
      quadruple therapy or triple therapy for 14 days remains unknown.

      Therefore, we aim to compare the eradication rates and long term re-infection rates of
      quadruple therapy for 10 days versus non-bismuth quadruple therapy for 10 days vs. triple
      therapy for 14 days.

      Methods: This will be a multi-center, open labeled, randomized control trial Patients: H.
      pylori infected patients who have willingness to receive eradication therapy

      Testing for H. pylori infection Before First Line Ttreatment

      (1)Any two positive of CLO test, histology, serology and culture or a positive UBT will be
      considered as H. pylori infected

      After First Line Treatment: C13-UBT will be used to assess the existence of H. pylori 6-8
      weeks after first line therapy.

      Long term reinfection: C13-UBT will be used to assess the recurrence of H. pylori 1 year
      after eradication therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First line therapy: open labeled, randomized control trial, randomized into one of the three
      groups Group (A): triple therapy for 14 days D1-D14: (lansoprazole 30mg + clarithromycin
      500mg + amoxicillin 1gm) bid Group (B): non-bismuth quadruple therapy for 10 days D1-D10:
      lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg
      bid Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid +
      colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid

      Second line therapy: patients who fail from first line treatment will be rescue with the
      following treatment Group (A) Patient who fail from triple therapy will be retreated with
      bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth
      subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid Group (B) Patient
      who fail from non-bismuth quadruple therapy will be retreated with bismuth quadruple therapy
      for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid +
      metronidazole 500mg tid + tetracycline 500mg tid Group (C) Patients who fail from bismuth
      quadruple therapy will be retreated with non-bismuth quadruple therapy for 10 days D1-D10:
      lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg
      bid
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Eradication rate for H. pylori</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Eradication rate in the first line according to intention to treat (ITT) and per-protocol (PP) analysis in the three treatment groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of each treatments</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>(1)	Incidence of adverse effects in the first line therapy in the three treatment groups</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Reinfection rate</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Eradication rates in the second line treatment in the three treatment groups
Overall eradication rates after first line and second line treatment in the three treatment groups
Antibiotic resistance of gut flora after first line and second line treatments in the three treatment groups
Changes of gut microbiota in the three treatment groups
Re-infection rate one year after eradication therapy</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group (A): triple therapy for 14 days D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-bismuth quadruple therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group (B): non-bismuth quadruple therapy for 10 days: lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bismuth quadruple therapy for 10 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group (C): bismuth quadruple therapy for 10 days D1-D10: lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triple, quadruple, non-bismuth quadruple therapy</intervention_name>
    <description>triple therapy, quadruple therapy, non-bismuth quadruple therapy</description>
    <arm_group_label>Triple therapy</arm_group_label>
    <arm_group_label>non-bismuth quadruple therapy</arm_group_label>
    <arm_group_label>bismuth quadruple therapy for 10 days</arm_group_label>
    <other_name>Group (A): triple therapy for 14 days</other_name>
    <other_name>Group (B): non-bismuth quadruple therapy for 10 days</other_name>
    <other_name>Group (C): bismuth quadruple therapy for 10 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients aged greater than 20 years who have H. pylori infection without prior eradication
        therapy and are willing to receive the sequential therapy will be eligible for enrolment.
        Written informed consents will be obtained from all patients prior to enrollment.

        Exclusion Criteria:

        Patients will be excluded from the study if any one of the following criteria is present:
        (1) children and teenagers aged less than 20 years, (2) history of gastrectomy, (3)gastric
        malignancy, including adenocarcinoma and lymphoma, (4) previous allergic reaction to
        antibiotics (amoxicillin, clarithromycin, metronidazole, or levofloxacin) and prompt pump
        inhibitors (lansoprazole), (5)contraindication to treatment drugs, (6) pregnant or
        lactating women, (7) severe concurrent diseases, and (8) Patients who cannot give informed
        consent by himself or herself.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Shiang Wu, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital, Taipei, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyh-Ming Liou, MD, PhD</last_name>
    <email>dtmed046@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ming-Shiang Wu</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jyh-Ming Liou, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ming-Shiang Wu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jyh-Ming Liou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mei-Jyh Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chien-Chun Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Yun-Lin County</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chieh-Chang Chen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chieh-Chang Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji-Yuh Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Jen Fang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>July 21, 2013</lastchanged_date>
  <firstreceived_date>July 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Taiwan University Hospital</investigator_affiliation>
    <investigator_full_name>National Taiwan University Hospital</investigator_full_name>
    <investigator_title>Department of Internal Medicine, National Taiwan University Hospital</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bismuth</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
